News Releases :: Sutro Biopharma, Inc. (STRO)

Apr 2, 2024 1:00 am EDT

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024 4:30 pm EDT

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Feb 6, 2024 4:05 pm EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

Jan 4, 2024 4:05 pm EST

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 14, 2023 4:05 pm EST

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Dec 11, 2023 4:05 pm EST

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023 4:05 pm EST

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023 4:00 pm EST

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Nov 21, 2023 4:05 pm EST

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023 4:30 pm EST

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones